Repurposing Vitamins as SARS-CoV-2 3CLpro and RBD Inhibitors

Study Background and Research Question

The COVID-19 pandemic has driven an urgent search for effective therapeutic strategies targeting the molecular machinery of SARS-CoV-2. Key to viral replication and pathogenesis are two protein targets: the 3-chymotrypsin-like protease (3CL^pro, also known as M^pro), essential for processing viral polyproteins, and the receptor-binding domain (RBD) of the spike (S) protein, which mediates viral entry via the ACE2 receptor. Inhibiting these proteins can disrupt both entry and replication, making them high-value targets for antiviral therapeutics research. The referenced study (Eskandari, 2022) interrogates whether widely available, safe natural compounds—specifically vitamins—can be computationally repurposed as inhibitors for these crucial viral proteins.

Key Innovation from the Reference Study

The core innovation of the study lies in its systematic, in silico repurposing approach, leveraging molecular docking and dynamics simulations to identify vitamins and derivatives as potential inhibitors of both SARS-CoV-2 3CL^pro and the spike RBD. Unlike traditional drug discovery pipelines that focus on novel chemical entities, this work evaluates compounds with established safety profiles and global availability. The study’s dual-target screening—simultaneously addressing viral entry and replication inhibition—sets it apart from many prior single-target campaigns.

Methods and Experimental Design Insights

The authors performed virtual screening using a curated library of vitamin compounds sourced from a commercial database. The workflow comprised:

• Preparation of protein structures: 3CL^pro and spike RBD structures were retrieved and optimized for docking studies.
• Docking simulations: Each vitamin was docked against the RBD (targeting residues involved in ACE2 binding) and the active site of 3CL^pro (notably His41 and Cys145).
• Molecular dynamics (MD) simulations: Top-ranked compounds from docking were further evaluated for binding stability and interaction persistence.

This approach allowed for assessment not only of binding affinity but also of dynamic stability within the target sites, supporting a more nuanced interpretation of potential inhibitory efficacy.

Core Findings and Why They Matter

From the virtual screening and MD analyses, several vitamins and derivatives demonstrated strong and stable interactions with the target viral proteins. Specifically, bentiamine, folic acid, benfotiamine, and vitamin B12 were identified as promising RBD inhibitors, while bentiamine, folic acid, fursultiamine, and riboflavin showed favorable binding to 3CL^pro. Importantly, these compounds engaged critical residues at the S-protein–ACE2 interface (such as R403, K417, Y449, Y453, N501, and Y505) and within the 3CL^pro active site (His41, Cys145), according to the reference study. These interactions are essential for inhibiting viral entry and replication, suggesting potential for these vitamins to serve as adjuncts or starting points in antiviral development.

The findings are significant for several reasons:

• They expand the repertoire of candidate molecules for rapid deployment in COVID-19 research, particularly in resource-limited settings.
• The safety and accessibility of vitamins lower barriers to experimental follow-up and translational exploration.
• Direct targeting of the 3CL^pro protease aligns mechanistically with established inhibitors (e.g., PF-07321332/Nirmatrelvir), supporting the relevance of the study’s approach within the current antiviral paradigm.

Comparison with Existing Internal Articles

This reference study’s approach provides a complementary perspective to detailed analyses of advanced 3CL^pro inhibitors. For example, the internal article “Nirmatrelvir (PF-07321332): Structural Insights and Assay Strategies” describes the molecular design and structural optimization of Nirmatrelvir, a potent, selective oral 3CL^pro inhibitor. The vitamin repurposing study, by contrast, highlights structurally simpler compounds with established human use, providing a low-risk entry point for exploratory antiviral therapeutics research. Meanwhile, “Nirmatrelvir (PF-07321332): Mechanistic Mastery and Strategic Research Use” contextualizes how precise protease inhibition can inform translational COVID-19 studies—a theme echoed in the reference paper’s emphasis on 3CL^pro as a linchpin for viral replication inhibition.

For researchers seeking a broader comparison of natural compounds and established small molecules, the internal review “Repurposing Vitamins Against SARS-CoV-2: Insights from Docking of 3CLpro and Spike RBD” synthesizes similar findings and positions the vitamin approach within the rapidly evolving landscape of SARS-CoV-2 antiviral research.

Limitations and Transferability

While the in silico findings are promising, several limitations temper immediate translational impact:

• The study’s conclusions are based on computational docking and MD simulations; no in vitro or in vivo validation is provided.
• Binding affinity and stability do not guarantee functional inhibition, especially in complex cellular or organismal systems.
• The pharmacokinetics and required concentrations of vitamins for antiviral activity in humans are likely to differ from nutritional dosing, raising challenges for clinical application.
• Potential off-target effects and the impact of metabolic transformation were not assessed.

Nevertheless, these limitations are characteristic of early-stage drug repurposing research and underscore the value of follow-up experimental studies. The findings provide a rational starting point for integrating safe, accessible molecules into broader antiviral screening workflows.

Protocol Parameters

• Protein Structure Preparation: Use high-resolution structures of SARS-CoV-2 3CL^pro (e.g., PDB 6LU7) and spike RBD for accurate docking.
• Ligand Library Selection: Curate vitamin compounds with known safety profiles for initial screening.
• Docking Grid Definition: Focus on the catalytic dyad (His41, Cys145) for 3CL^pro; target ACE2-interacting residues (e.g., R403, K417, Y449, Y453, N501, Y505) on the spike RBD.
• Molecular Dynamics Simulation: Perform at least 100 ns MD simulations to verify binding stability of top candidates.
• Experimental Validation (Recommended): Follow up computational hits with enzymatic inhibition assays and cell-based viral replication models.

Why this cross-domain matters, maturity, and limitations

Repurposing vitamins—molecules with established safety and widespread availability—offers a bridge between nutritional biochemistry and antiviral therapeutics research. This cross-domain approach is attractive for rapid-response scenarios and can inform the rational design of new inhibitors based on natural scaffolds. However, the maturity of this strategy is limited by the lack of preclinical and clinical data verifying antiviral efficacy at physiologically achievable concentrations. Thus, while computational findings are encouraging, rigorous experimental work is required before translating these insights into clinical practice.

Research Support Resources

For researchers aiming to model or experimentally validate SARS-CoV-2 3CL^pro inhibition, established small molecules such as Nirmatrelvir (PF-07321332) (SKU B8579, APExBIO) provide a robust benchmark. Nirmatrelvir is a well-characterized, orally bioavailable inhibitor with specific activity against the 3CL^pro enzyme, making it suitable for comparative assays and mechanistic studies. Integrating such reference compounds into antiviral research workflows can enhance the interpretability and translational value of results from both natural and synthetic inhibitor screens.